[Expression of COP9, JAK2, HSP and NADH in ovarian carcinoma tissues after taxol-chemotherapy and their significance].
To study the expression of COP9, JAK2, HSP and NADH genes in ovarian carcinoma tissues after taxol-chemotherapy and their significance. The up-regulated genes of JAK2, HSP, NADH and the down-regulated gene of COP9, which were revealed by micro-array from our previous study were examined by RT-PCR and real-time-PCR in 33 cases of ovarian cancer who previously received taxol-based chemotherapy (group 1), and 21 cases of ovarian cancer who never received chemotherapy before operation (group 2). The expression rate of COP9 gene in group 1 was detected markedly lower than that in group 2 (39% vs 95%, P < 0.01); whereas the expression rates of JAK2, HSP and NADH in group 1 were significantly higher that those in group 2 (91%, 97%, 94% vs 29%, 48%, 43%; all P < 0.05). And the expression of COP9, HSP and NADH genes had no significant differences among histological grades. However, a significantly higher expression of JAK2 gene was seen in grade 3 than in grade 1-2 (P < 0.01). No significant difference in the expression rates of the 4 genes was seen among various tumor types or chemotherapy courses (P > 0.05). Real-time PCR showed that the level of COP9 gene copies of group 1 was significantly lower than that of group 2 (568, 1866 respectively; P < 0.05). However, HSP, JAK2 and NADH genes had significantly higher copy numbers in group 1 than in group 2 (5766, 7653, 3200 in group 1 and 3341, 3094, 1522 in group 2, respectively; all P < 0.05). In the subgroup that received 6-10 chemotherapy courses, the copy concentrations of JAK2, HSP, NADH genes were higher than those in the subgroup that received 2-4 chemotherapy courses (all P < 0.05). In addition, we found a higher copy concentrations of JAK2, HSP, NADH genes in grade 3 than in grade 1-2 (all P < 0.05). Though no significant differences in gene copy concentrations of the 4 genes were seen among variable tumor types. In stage IV, the copy concentrations of HSP and NADH genes were higher than those in stage III (P < 0.01, P < 0.05 respectively), but the copy concentrations of COP9, JAK2 genes had no significant differences (both P > 0.05). There were positive correlations among JAK2, HSP and NADH genes (r = 0.56, 0.44, 0.57 respectively, all P < 0.01). COP9 gene was found to have a negative correlation with JAK2 gene (r = -0.48; P < 0.01), but not with HSP and NADH genes (r = -0.18, -0.06, respectively; both P > 0.05). The down-regulation of COP9 gene and up-regulation of JAK2, HSP, and NADH genes are related to the mechanism of drug-resistance in ovarian cancer.